Neurobiological Technologies fades to black

Poisoned by the late-stage failure of its venom-based stroke drug late last year, Neurobiological Technologies says it will close up shop and dissolve the company. The developer had $24 million on hand at the end of the first half, but after Viprinex flunked a late-stage trial in December the biotech laid off most of its staff and went hunting for a buyer. With no buyer stepping forward, Neurobiological says it will hand out its remaining cash to shareholders. Release | Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.